Diabetes Clinical Trial
Official title:
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Uptake in Human
Objective - A variety of herbal, over-the-counter preparations of tea leaves are said to
reduce the rate of absorption of fat ( allegedly via inhibition of pancreatic lipase) and
carbohydrate (via inhibition of carbohydrate digestion and blocking of glucose transport by
the intestinal mucosa). There has been some study of the ability of these products to reduce
the blood glucose increase observed after a carbohydrate meal and to reduce blood
cholesterol levels in chronic studies. The purpose of the present study is to objectively
determine if one cup of “tea” made from a combination of three types of tea leaves
(mulberry, black and green tea) can cause malabsorption of carbohydrate and fat taken in
conjunction with the tea.
Research Design - The study will consist of a double blind, placebo controlled crossover
study in 20 healthy subjects. On one of two days (one week apart) the subjects will ingest a
standard meal consisting of 30 g of sucrose (in the tea) and 30 g of starch in the form of
white rice plus 10 g of fat as butter. To measure triglyceride absorption, each meal will
also contain 250 mg of 13-C labeled triolein. Triolein is a commonly ingested fat consisting
of glycerol bound to three oleic acids. 13-C is a stable (non-radioactive) isotope of
carbon. On one of the test days the subjects (randomly) will concurrently consume the active
preparation, a tea containing extracts of the three types of tea leave described above plus
the meal, and on the other test day they will consume the meal with a liquid placebo
preparation (warm water, sugar and food coloring). Subjects will provide a breath sample
before and at hourly intervals for 8 hours after ingestion of the meal. Carbohydrate
malabsorption will be determined by the hydrogen concentration in the breath samples and fat
malabsorption by the concentration of 13-CO2 in the breath samples.
Clinical Significance - An increase in breath hydrogen indicates carbohydrate malabsoption
and a low 13-CO2 indicates lipid malabsorption. Objective evidence that the tea leaf extract
actually induces carbohydrate and/or fat malabsorption could provide the basis for further
studies.
One of the commonly cited beneficial effects of tea is its ability to induce weight loss.
Support for this contention include a controlled human trial showing increased weight loss
when tea was added to a dietary regimen, and a mouse study demonstrating that administration
of a tea extract with a high fat diet eliminated the weight gain observed in the absence of
tea. Several different mechanisms have been postulated to account for this weight control.
Multiple studies have reported modest increases in energy expenditure associated with
ingestion of oolong or green teas. In addition, tea could inhibit the absorption of
carbohydrate and/or fat. Studies supporting the possibility of carbohydrate malabsorption
include a in vitro studies showing that constituents of tea inhibit the activity of
carbohydrate digesting enzymes (α-amylase and α-glucosidase, and the mucosal uptake of
glucose via an interaction with sodium dependent glucose transporters. The in vitro
demonstration that tea extracts inhibit pancreatic lipase activity suggests that tea might
interfere with triglyceride absorption.
However, there have been no in vivo studies in humans or animals showing that tea
preparations actually are capable of causing malabsorption of either carbohydrate or fat. In
the present study, we utilized measurements of breath H2 and 13CO2 to investigate the
ability of a mixture of black, green and mulberry tea leaf extracts to induce malabsorption
of carbohydrate and fat in healthy volunteers.
Protocol - The study group consisted of 20 healthy volunteers (ages 23 to 52, 10 females and
10 males). The subjects fasted after their usual dinner on the day preceding the study until
the following morning (approximately 8 am) when the experiments were performed. After
collection of baseline breath samples for H2 and 13CO2 analysis, the subjects ingested the
test meal that consisted of cooked white rice and butter. The rice was boiled for20 minutes,
and then individual portions (176 g, which contained 50 g of carbohydrate) were weighed and
frozen with 10g of butter. Immediately prior to ingestion, the meals were warmed in a
microwave oven, and 0.2 g of 1,1,1-13C-triolein (Cambridge Isotope Laboratories, Andover,
MA) was thoroughly mixed into the meal. Concurrent with ingestion of the meal, the subjects
randomly were assigned to drink either 500 ml of the warm active tea preparation containing
10 g of sucrose or 500 ml of a placebo preparation that also contained 10 g of sucrose.
Breath samples were then collected at hourly intervals for eight hours. At the end of each
test period, subjects were asked to rate a variety of symptoms including nausea, bloating,
abdominal discomfort, and rectal gas (as well as obfuscating symptoms) on a previously
described linear scale that ranged from zero (none) to 4 (severe). In addition, the number
of loose bowel movements were noted. One week later the test was repeated with the subjects
receiving the opposite preparation from that used in the initial study. The study was
approved by the Human Studies Subcommittee of the Mpls. VA Medical center and informed
consent was obtained from all subjects.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
| Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
| Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
| Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
| Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
| Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
| Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
| Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
| Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
| Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
| Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
| Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |